GlassScriptPhysician profile
Richard Decarolis
NPI 1306801444
$829.15
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $117 · 2021: $20.40 · 2022: $88.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $128.75 | 2019 | |
| Novo Nordisk INC | $125.41 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $98.50 | 2019-2020 | |
| Pfizer INC. | $60.65 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $58.12 | 2022 | |
| Amgen INC. | $56.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.47 | 2019 | |
| Glaxosmithkline, LLC. | $38.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.41 | 2019 | |
| Abbvie INC. | $30.62 | 2022 | |
| Sanofi Pasteur INC. | $27.66 | 2019 | |
| Merck Sharp & Dohme LLC | $27.14 | 2019 | |
| Indivior INC. | $20.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.30 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.87 | 2020 | |
| Gilead Sciences, INC. | $16.26 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.63 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Decarolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.